Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6673944

CN[C@H](C=C(C)C(=O)O)C(C)C.O=C(O)C(F)(F)F

nearest known ligand 0.32

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6673938 1.00 TUBB1 (0.32) TUBB1
SCHEMBL5578339 0.89 TUBB1 (0.33) TUBB1
SCHEMBL22643755 0.89 TUBB1 (0.33) TUBB1
SCHEMBL5578335 0.89 TUBB1 (0.33) TUBB1
SCHEMBL16862667 0.89 TUBB1 (0.33) TUBB1
SCHEMBL16861443 0.89 TUBB1 (0.33) TUBB1
Hydrochloric Acid SCHEMBL6669635 0.87 TUBB1 (0.33) TUBB1
Hydrochloric Acid SCHEMBL6669625 0.87 TUBB1 (0.33) TUBB1
SCHEMBL6673942 0.76
Trifluoroacetic Acid SCHEMBL30910755 0.76 GABRP (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040121965-A1 Method of treating resistant tumors WYETH HOLDINGS CORPORATION (US) 2004-06-24 US disclosed
WO-2004026293-A2 HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS WYETH HOLDINGS CORPORATION (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121965-A1 Method of treating resistant tumors SLC11A2, VHL, REN TUBB1 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.